DLVR Therapeutics Inc., a Toronto, Ontario, Canada-based biotechnology company focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle, has completed its seed funding round.
MaRS Innovation has joined the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in DLVR.
The company intends to use the additional funds to advance its small molecule chemotherapeutic program towards a pre-clinical regulatory package and continue development of its small interfering RNA (siRNA) program.
Founded in 2011 and led by President and CEO Mr. Frank Gleeson, DLVR is based on the technology developed by Dr. Gang Zheng of UHN.
In conjunction with the transaction, Raphael (Rafi) Hofstein, PhD, President and CEO of MaRS Innovation, will join the company’s board of directors; Parimal Nathwani, Vice-President of MaRS Innovation will become a member of the management team in a business development position.